| pubmed-article:3404256 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3404256 | lifeskim:mentions | umls-concept:C0001128 | lld:lifeskim |
| pubmed-article:3404256 | lifeskim:mentions | umls-concept:C0205360 | lld:lifeskim |
| pubmed-article:3404256 | lifeskim:mentions | umls-concept:C0205460 | lld:lifeskim |
| pubmed-article:3404256 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:3404256 | pubmed:dateCreated | 1988-9-12 | lld:pubmed |
| pubmed-article:3404256 | pubmed:abstractText | The stability of tauro-23-[75Se]selena-25-homocholic acid (SeHCAT) towards deconjugation by the enzyme cholylglycine hydrolase was compared with that of taurocholate: whereas taurocholate underwent 58% deconjugation within 2 hr, SeHCAT suffered only 8% deconjugation plus 5% conversion to an unknown product within 24 hr. Incubation of SeHCAT under anaerobic conditions for 48 hr at 37 degrees C with human fecal organisms resulted in considerable deconjugation, 7 alpha-dehydroxylation, and dehydrogenation. Twenty-four hours after the simultaneous administration of SeHCAT and tauro-[24-14C]cholate to a rabbit the recovery of 75Se in bile was 90% of that of 14C. Forty-eight hours following administration of SeHCAT to a second rabbit residual bile radioactivity revealed 80% deconjugation and dehydroxylation and 60% reconjugation with glycine. Although SeHCAT is more resistant than taurocholate towards modification by fecal bacterial enzymes, within the rabbit it follows the principal metabolic pathways of the natural bile acids. | lld:pubmed |
| pubmed-article:3404256 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3404256 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3404256 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3404256 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3404256 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3404256 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3404256 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3404256 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3404256 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3404256 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3404256 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:3404256 | pubmed:issn | 0161-5505 | lld:pubmed |
| pubmed-article:3404256 | pubmed:author | pubmed-author:COPPJ DJD | lld:pubmed |
| pubmed-article:3404256 | pubmed:author | pubmed-author:MonksRR | lld:pubmed |
| pubmed-article:3404256 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3404256 | pubmed:volume | 29 | lld:pubmed |
| pubmed-article:3404256 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3404256 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3404256 | pubmed:pagination | 1411-8 | lld:pubmed |
| pubmed-article:3404256 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:3404256 | pubmed:meshHeading | pubmed-meshheading:3404256-... | lld:pubmed |
| pubmed-article:3404256 | pubmed:meshHeading | pubmed-meshheading:3404256-... | lld:pubmed |
| pubmed-article:3404256 | pubmed:meshHeading | pubmed-meshheading:3404256-... | lld:pubmed |
| pubmed-article:3404256 | pubmed:meshHeading | pubmed-meshheading:3404256-... | lld:pubmed |
| pubmed-article:3404256 | pubmed:meshHeading | pubmed-meshheading:3404256-... | lld:pubmed |
| pubmed-article:3404256 | pubmed:meshHeading | pubmed-meshheading:3404256-... | lld:pubmed |
| pubmed-article:3404256 | pubmed:meshHeading | pubmed-meshheading:3404256-... | lld:pubmed |
| pubmed-article:3404256 | pubmed:meshHeading | pubmed-meshheading:3404256-... | lld:pubmed |
| pubmed-article:3404256 | pubmed:meshHeading | pubmed-meshheading:3404256-... | lld:pubmed |
| pubmed-article:3404256 | pubmed:meshHeading | pubmed-meshheading:3404256-... | lld:pubmed |
| pubmed-article:3404256 | pubmed:meshHeading | pubmed-meshheading:3404256-... | lld:pubmed |
| pubmed-article:3404256 | pubmed:meshHeading | pubmed-meshheading:3404256-... | lld:pubmed |
| pubmed-article:3404256 | pubmed:year | 1988 | lld:pubmed |
| pubmed-article:3404256 | pubmed:articleTitle | Biologic stability of tauro-23-[75Se] selena-25-homocholic acid. | lld:pubmed |
| pubmed-article:3404256 | pubmed:affiliation | Amersham International plc, Bucks, United Kingdom. | lld:pubmed |
| pubmed-article:3404256 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3404256 | pubmed:publicationType | Comparative Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3404256 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3404256 | lld:pubmed |
